BRAIN Biotech AG (LTS:0RFI) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RFI BRAIN Biotech AG LTS:0RFI
60 GF Score
Price €2.91
GF Value €2.70
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BRAIN Biotech AG Valuation Rank Related Terms

LTS:0RFI
60GF Score
BRAIN Biotech AG LTS:0RFI
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BRAIN Biotech AG (LTS:0RFI) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.91 is trading 7.8% above its estimated GF Value™ of €2.70. GuruFocus considers BRAIN Biotech AG to be Fairly Valued.

Key valuation signals for LTS:0RFI:

  • Valuation Rank:
  • GF Value™: €2.70 vs. price of €2.91 (7.8% above fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RFI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Other Exchanges BNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
60GF Score

Get the complete analysis for LTS:0RFI

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.91
Price
€2.70
GF Value